NASDAQ:LGVN - Nasdaq - US54303L2034 - Common Stock - Currency: USD
1.56
-0.08 (-4.88%)
The current stock price of LGVN is 1.56 USD. In the past month the price decreased by -8.24%. In the past year, price decreased by -69.88%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Longeveron Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Miami, Florida and currently employs 23 full-time employees. The company went IPO on 2021-02-12. Longeveron Inc. is a clinical-stage biotechnology company. The firm is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The firm's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The firm is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The firm has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
LONGEVERON INC-A
1951 NW 7th Ave, Ste 520
Miami FLORIDA 33136 US
CEO: Geoff Green
Employees: 24
Company Website: https://www.longeveron.com/
Investor Relations: http://investors.longeveron.com/overview/default.aspx
Phone: 13053027158
The current stock price of LGVN is 1.56 USD. The price decreased by -4.88% in the last trading session.
The exchange symbol of LONGEVERON INC-A is LGVN and it is listed on the Nasdaq exchange.
LGVN stock is listed on the Nasdaq exchange.
9 analysts have analysed LGVN and the average price target is 9.05 USD. This implies a price increase of 480.29% is expected in the next year compared to the current price of 1.56. Check the LONGEVERON INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LONGEVERON INC-A (LGVN) has a market capitalization of 23.15M USD. This makes LGVN a Nano Cap stock.
LONGEVERON INC-A (LGVN) currently has 24 employees.
LONGEVERON INC-A (LGVN) has a support level at 1.51 and a resistance level at 1.62. Check the full technical report for a detailed analysis of LGVN support and resistance levels.
The Revenue of LONGEVERON INC-A (LGVN) is expected to grow by 165.46% in the next year. Check the estimates tab for more information on the LGVN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LGVN does not pay a dividend.
LONGEVERON INC-A (LGVN) will report earnings on 2025-03-07, after the market close.
LONGEVERON INC-A (LGVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.28).
The outstanding short interest for LONGEVERON INC-A (LGVN) is 4.88% of its float. Check the ownership tab for more information on the LGVN short interest.
ChartMill assigns a fundamental rating of 4 / 10 to LGVN. No worries on liquidiy or solvency for LGVN as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months LGVN reported a non-GAAP Earnings per Share(EPS) of -6.28. The EPS increased by 35.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -91.5% | ||
ROE | -106.79% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to LGVN. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 65.95% and a revenue growth 165.46% for LGVN